Salute e Benessere
Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK
The MHRA's marketing authorization of Oczyesa is based on the results from a comprehensive clinical program comprising seven clinical studies, including two Phase 3 studies within the ACROINNOVA program.
Oczyesa is formulated using Camurus' proprietary FluidCrystal technology. The product is designed for convenient once-monthly, subcutaneous self-administration using a pre-filled autoinjector pen with a hidden, thin needle.
Oczyesa was granted marketing authorization in the EU by the European Commission on 30 June 2025 .
Fredrik Tiberg , President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
This information was submitted for publication at 4.45 pm CET on 28 August 2025 .
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/camurus-ab/r/camurus-announces-approval-of-oczyesa--for-the-treatment-of-acromegaly-in-the-uk,c4226147
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/camurus-announces-approval-of-oczyesa-for-the-treatment-of-acromegaly-in-the-uk-302541276.html